CA2308277A1 - Hemoglobin with chemically introduced disulfide cross-links and preparation thereof - Google Patents
Hemoglobin with chemically introduced disulfide cross-links and preparation thereof Download PDFInfo
- Publication number
- CA2308277A1 CA2308277A1 CA002308277A CA2308277A CA2308277A1 CA 2308277 A1 CA2308277 A1 CA 2308277A1 CA 002308277 A CA002308277 A CA 002308277A CA 2308277 A CA2308277 A CA 2308277A CA 2308277 A1 CA2308277 A1 CA 2308277A1
- Authority
- CA
- Canada
- Prior art keywords
- hemoglobin
- cross
- disulfide
- linked
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 108010054147 Hemoglobins Proteins 0.000 title claims abstract description 107
- 102000001554 Hemoglobins Human genes 0.000 title claims abstract description 107
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 title claims abstract description 35
- 238000002360 preparation method Methods 0.000 title description 4
- 239000003153 chemical reaction reagent Substances 0.000 claims abstract description 47
- 238000006243 chemical reaction Methods 0.000 claims abstract description 42
- INGWEZCOABYORO-UHFFFAOYSA-N 2-(furan-2-yl)-7-methyl-1h-1,8-naphthyridin-4-one Chemical compound N=1C2=NC(C)=CC=C2C(O)=CC=1C1=CC=CO1 INGWEZCOABYORO-UHFFFAOYSA-N 0.000 claims abstract description 31
- -1 cysteinyl amide Chemical class 0.000 claims abstract description 24
- 125000003396 thiol group Chemical group [H]S* 0.000 claims abstract description 18
- 108010002255 deoxyhemoglobin Proteins 0.000 claims abstract description 16
- 239000003638 chemical reducing agent Substances 0.000 claims abstract description 7
- CAAULPUQFIIOTL-UHFFFAOYSA-N methyl dihydrogen phosphate Chemical compound COP(O)(O)=O CAAULPUQFIIOTL-UHFFFAOYSA-N 0.000 claims abstract description 6
- 230000000694 effects Effects 0.000 claims description 11
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 8
- 238000006894 reductive elimination reaction Methods 0.000 claims description 6
- 229910019142 PO4 Inorganic materials 0.000 claims description 5
- 239000010452 phosphate Substances 0.000 claims description 5
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 125000001475 halogen functional group Chemical group 0.000 claims description 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 2
- 150000001875 compounds Chemical class 0.000 abstract description 21
- 102000018146 globin Human genes 0.000 abstract description 19
- 108060003196 globin Proteins 0.000 abstract description 19
- 230000009467 reduction Effects 0.000 abstract description 10
- 239000000126 substance Substances 0.000 abstract description 9
- 229910052757 nitrogen Inorganic materials 0.000 abstract description 8
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract description 7
- 229910052760 oxygen Inorganic materials 0.000 abstract description 7
- 239000001301 oxygen Substances 0.000 abstract description 7
- 125000003277 amino group Chemical group 0.000 abstract description 4
- 238000012377 drug delivery Methods 0.000 abstract 1
- 108010036302 hemoglobin AS Proteins 0.000 abstract 1
- 239000000047 product Substances 0.000 description 32
- 102000004169 proteins and genes Human genes 0.000 description 22
- 108090000623 proteins and genes Proteins 0.000 description 22
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 22
- 235000018102 proteins Nutrition 0.000 description 21
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 19
- 239000000243 solution Substances 0.000 description 18
- 238000000034 method Methods 0.000 description 16
- XOHUEYCVLUUEJJ-UWTATZPHSA-N 2,3-bisphospho-D-glyceric acid Chemical compound OP(=O)(O)O[C@@H](C(=O)O)COP(O)(O)=O XOHUEYCVLUUEJJ-UWTATZPHSA-N 0.000 description 13
- 238000004132 cross linking Methods 0.000 description 13
- 238000004128 high performance liquid chromatography Methods 0.000 description 11
- 238000004007 reversed phase HPLC Methods 0.000 description 10
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 9
- 238000004458 analytical method Methods 0.000 description 9
- 239000000463 material Substances 0.000 description 9
- 230000008569 process Effects 0.000 description 9
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 8
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 8
- 239000000203 mixture Substances 0.000 description 8
- 108090000765 processed proteins & peptides Proteins 0.000 description 8
- 239000007993 MOPS buffer Substances 0.000 description 7
- 230000015572 biosynthetic process Effects 0.000 description 7
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- 238000003776 cleavage reaction Methods 0.000 description 6
- 239000000543 intermediate Substances 0.000 description 6
- 238000007254 oxidation reaction Methods 0.000 description 6
- 239000011541 reaction mixture Substances 0.000 description 6
- 230000002829 reductive effect Effects 0.000 description 6
- FVAUCKIRQBBSSJ-UHFFFAOYSA-M sodium iodide Chemical compound [Na+].[I-] FVAUCKIRQBBSSJ-UHFFFAOYSA-M 0.000 description 6
- 239000000872 buffer Substances 0.000 description 5
- 230000007017 scission Effects 0.000 description 5
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 4
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 4
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 4
- 150000002019 disulfides Chemical class 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- 238000012986 modification Methods 0.000 description 4
- 108091005573 modified proteins Proteins 0.000 description 4
- 102000035118 modified proteins Human genes 0.000 description 4
- 230000003647 oxidation Effects 0.000 description 4
- 235000021317 phosphate Nutrition 0.000 description 4
- 241000894007 species Species 0.000 description 4
- 125000001424 substituent group Chemical group 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- UGFAIRIUMAVXCW-UHFFFAOYSA-N Carbon monoxide Chemical compound [O+]#[C-] UGFAIRIUMAVXCW-UHFFFAOYSA-N 0.000 description 3
- 108010003320 Carboxyhemoglobin Proteins 0.000 description 3
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 3
- 239000004202 carbamide Substances 0.000 description 3
- 229910002091 carbon monoxide Inorganic materials 0.000 description 3
- 239000007795 chemical reaction product Substances 0.000 description 3
- 230000021615 conjugation Effects 0.000 description 3
- 230000029087 digestion Effects 0.000 description 3
- 239000000539 dimer Substances 0.000 description 3
- 238000010265 fast atom bombardment Methods 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 238000010353 genetic engineering Methods 0.000 description 3
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 3
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 238000010183 spectrum analysis Methods 0.000 description 3
- 150000003573 thiols Chemical group 0.000 description 3
- SGTOKVHOVUZTIK-OWOJBTEDSA-N (e)-4-[(3,5-dibromo-2-hydroxyphenyl)methoxy]-4-oxobut-2-enoic acid Chemical compound OC(=O)\C=C\C(=O)OCC1=CC(Br)=CC(Br)=C1O SGTOKVHOVUZTIK-OWOJBTEDSA-N 0.000 description 2
- 108010088751 Albumins Proteins 0.000 description 2
- 102000009027 Albumins Human genes 0.000 description 2
- ATRRKUHOCOJYRX-UHFFFAOYSA-N Ammonium bicarbonate Chemical compound [NH4+].OC([O-])=O ATRRKUHOCOJYRX-UHFFFAOYSA-N 0.000 description 2
- 229910000013 Ammonium bicarbonate Inorganic materials 0.000 description 2
- 239000004971 Cross linker Substances 0.000 description 2
- LEVWYRKDKASIDU-QWWZWVQMSA-N D-cystine Chemical class OC(=O)[C@H](N)CSSC[C@@H](N)C(O)=O LEVWYRKDKASIDU-QWWZWVQMSA-N 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 229920005654 Sephadex Polymers 0.000 description 2
- 239000012507 Sephadex™ Substances 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
- 239000007983 Tris buffer Substances 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 235000012538 ammonium bicarbonate Nutrition 0.000 description 2
- 239000001099 ammonium carbonate Substances 0.000 description 2
- 125000000129 anionic group Chemical group 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- OWMVSZAMULFTJU-UHFFFAOYSA-N bis-tris Chemical compound OCCN(CCO)C(CO)(CO)CO OWMVSZAMULFTJU-UHFFFAOYSA-N 0.000 description 2
- 239000003633 blood substitute Substances 0.000 description 2
- FAKRSMQSSFJEIM-RQJHMYQMSA-N captopril Chemical compound SC[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O FAKRSMQSSFJEIM-RQJHMYQMSA-N 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000007385 chemical modification Methods 0.000 description 2
- 239000011243 crosslinked material Substances 0.000 description 2
- 125000002228 disulfide group Chemical group 0.000 description 2
- 238000000132 electrospray ionisation Methods 0.000 description 2
- DNJIEGIFACGWOD-UHFFFAOYSA-N ethyl mercaptane Natural products CCS DNJIEGIFACGWOD-UHFFFAOYSA-N 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 150000003278 haem Chemical class 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 238000004255 ion exchange chromatography Methods 0.000 description 2
- 229910052742 iron Inorganic materials 0.000 description 2
- 238000004949 mass spectrometry Methods 0.000 description 2
- 238000001819 mass spectrum Methods 0.000 description 2
- 230000001590 oxidative effect Effects 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- UEZVMMHDMIWARA-UHFFFAOYSA-M phosphonate Chemical compound [O-]P(=O)=O UEZVMMHDMIWARA-UHFFFAOYSA-M 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- LVTJOONKWUXEFR-FZRMHRINSA-N protoneodioscin Natural products O(C[C@@H](CC[C@]1(O)[C@H](C)[C@@H]2[C@]3(C)[C@H]([C@H]4[C@@H]([C@]5(C)C(=CC4)C[C@@H](O[C@@H]4[C@H](O[C@H]6[C@@H](O)[C@@H](O)[C@@H](O)[C@H](C)O6)[C@@H](O)[C@H](O[C@H]6[C@@H](O)[C@@H](O)[C@@H](O)[C@H](C)O6)[C@H](CO)O4)CC5)CC3)C[C@@H]2O1)C)[C@H]1[C@H](O)[C@H](O)[C@H](O)[C@@H](CO)O1 LVTJOONKWUXEFR-FZRMHRINSA-N 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
- 235000009518 sodium iodide Nutrition 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 239000003774 sulfhydryl reagent Substances 0.000 description 2
- 230000034005 thiol-disulfide exchange Effects 0.000 description 2
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 1
- 238000005160 1H NMR spectroscopy Methods 0.000 description 1
- NVWSLNRSPZAQOK-UHFFFAOYSA-N 3,4-dibromo-2-hydroxybenzoic acid Chemical group OC(=O)C1=CC=C(Br)C(Br)=C1O NVWSLNRSPZAQOK-UHFFFAOYSA-N 0.000 description 1
- TVZRAEYQIKYCPH-UHFFFAOYSA-N 3-(trimethylsilyl)propane-1-sulfonic acid Chemical compound C[Si](C)(C)CCCS(O)(=O)=O TVZRAEYQIKYCPH-UHFFFAOYSA-N 0.000 description 1
- 238000004679 31P NMR spectroscopy Methods 0.000 description 1
- 239000005541 ACE inhibitor Substances 0.000 description 1
- 102400000059 Arg-vasopressin Human genes 0.000 description 1
- 101800001144 Arg-vasopressin Proteins 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 101100328486 Caenorhabditis elegans cni-1 gene Proteins 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- KKUKTXOBAWVSHC-UHFFFAOYSA-N Dimethylphosphate Chemical compound COP(O)(=O)OC KKUKTXOBAWVSHC-UHFFFAOYSA-N 0.000 description 1
- VTLYFUHAOXGGBS-UHFFFAOYSA-N Fe3+ Chemical compound [Fe+3] VTLYFUHAOXGGBS-UHFFFAOYSA-N 0.000 description 1
- 238000005033 Fourier transform infrared spectroscopy Methods 0.000 description 1
- 108010051815 Glutamyl endopeptidase Proteins 0.000 description 1
- 239000006173 Good's buffer Substances 0.000 description 1
- 101000825742 Homo sapiens Somatoliberin Proteins 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 108010061951 Methemoglobin Proteins 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- 108010064719 Oxyhemoglobins Proteins 0.000 description 1
- 102000007079 Peptide Fragments Human genes 0.000 description 1
- 108010033276 Peptide Fragments Proteins 0.000 description 1
- 108010001267 Protein Subunits Proteins 0.000 description 1
- 101100073357 Streptomyces halstedii sch2 gene Proteins 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- UCKMPCXJQFINFW-UHFFFAOYSA-N Sulphide Chemical compound [S-2] UCKMPCXJQFINFW-UHFFFAOYSA-N 0.000 description 1
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical group [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 238000005917 acylation reaction Methods 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 150000003862 amino acid derivatives Chemical class 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 description 1
- 238000005571 anion exchange chromatography Methods 0.000 description 1
- 229940124332 anorexigenic agent Drugs 0.000 description 1
- 230000002891 anorexigenic effect Effects 0.000 description 1
- 239000002259 anti human immunodeficiency virus agent Substances 0.000 description 1
- 230000001028 anti-proliverative effect Effects 0.000 description 1
- 230000002785 anti-thrombosis Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 239000012062 aqueous buffer Substances 0.000 description 1
- KBZOIRJILGZLEJ-LGYYRGKSSA-N argipressin Chemical compound C([C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@@H](C(N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N1)=O)N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(N)=O)C1=CC=CC=C1 KBZOIRJILGZLEJ-LGYYRGKSSA-N 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 230000001746 atrial effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 229910021538 borax Inorganic materials 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 229960000830 captopril Drugs 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 125000002843 carboxylic acid group Chemical group 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 238000001311 chemical methods and process Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- NKLPQNGYXWVELD-UHFFFAOYSA-M coomassie brilliant blue Chemical compound [Na+].C1=CC(OCC)=CC=C1NC1=CC=C(C(=C2C=CC(C=C2)=[N+](CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=2C=CC(=CC=2)N(CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=C1 NKLPQNGYXWVELD-UHFFFAOYSA-M 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 239000003431 cross linking reagent Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 229960003067 cystine Drugs 0.000 description 1
- 238000010520 demethylation reaction Methods 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 150000001991 dicarboxylic acids Chemical class 0.000 description 1
- MBTOOKBKBYXTCE-UHFFFAOYSA-L disodium;methyl phosphate Chemical compound [Na+].[Na+].COP([O-])([O-])=O MBTOOKBKBYXTCE-UHFFFAOYSA-L 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000012039 electrophile Substances 0.000 description 1
- 238000000119 electrospray ionisation mass spectrum Methods 0.000 description 1
- 238000001976 enzyme digestion Methods 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- HWJHWSBFPPPIPD-UHFFFAOYSA-N ethoxyethane;propan-2-one Chemical compound CC(C)=O.CCOCC HWJHWSBFPPPIPD-UHFFFAOYSA-N 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 238000001641 gel filtration chromatography Methods 0.000 description 1
- 238000002523 gelfiltration Methods 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- 108010047412 hemoglobin L Proteins 0.000 description 1
- 239000004030 hiv protease inhibitor Substances 0.000 description 1
- 239000000413 hydrolysate Substances 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 238000002329 infrared spectrum Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 1
- 150000002605 large molecules Chemical class 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 238000000324 molecular mechanic Methods 0.000 description 1
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
- 239000012038 nucleophile Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 238000001139 pH measurement Methods 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 238000001394 phosphorus-31 nuclear magnetic resonance spectrum Methods 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000009145 protein modification Effects 0.000 description 1
- 239000012460 protein solution Substances 0.000 description 1
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 238000010188 recombinant method Methods 0.000 description 1
- 239000002461 renin inhibitor Substances 0.000 description 1
- 229940086526 renin-inhibitors Drugs 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000002390 rotary evaporation Methods 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 235000010339 sodium tetraborate Nutrition 0.000 description 1
- LMGRDVWNCARTPS-UHFFFAOYSA-M sodium;dimethyl phosphate Chemical compound [Na+].COP([O-])(=O)OC LMGRDVWNCARTPS-UHFFFAOYSA-M 0.000 description 1
- 125000006850 spacer group Chemical group 0.000 description 1
- 230000003595 spectral effect Effects 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 230000003335 steric effect Effects 0.000 description 1
- 238000012916 structural analysis Methods 0.000 description 1
- FRGKKTITADJNOE-UHFFFAOYSA-N sulfanyloxyethane Chemical compound CCOS FRGKKTITADJNOE-UHFFFAOYSA-N 0.000 description 1
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- QIQCZROILFZKAT-UHFFFAOYSA-N tetracarbon dioxide Chemical group O=C=C=C=C=O QIQCZROILFZKAT-UHFFFAOYSA-N 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 125000005147 toluenesulfonyl group Chemical group C=1(C(=CC=CC1)S(=O)(=O)*)C 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- WVLBCYQITXONBZ-UHFFFAOYSA-N trimethyl phosphate Chemical compound COP(=O)(OC)OC WVLBCYQITXONBZ-UHFFFAOYSA-N 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- BSVBQGMMJUBVOD-UHFFFAOYSA-N trisodium borate Chemical compound [Na+].[Na+].[Na+].[O-]B([O-])[O-] BSVBQGMMJUBVOD-UHFFFAOYSA-N 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- WFKWXMTUELFFGS-UHFFFAOYSA-N tungsten Chemical compound [W] WFKWXMTUELFFGS-UHFFFAOYSA-N 0.000 description 1
- 229910052721 tungsten Inorganic materials 0.000 description 1
- 239000010937 tungsten Substances 0.000 description 1
- 239000005526 vasoconstrictor agent Substances 0.000 description 1
- 229940124549 vasodilator Drugs 0.000 description 1
- 239000003071 vasodilator agent Substances 0.000 description 1
- 238000012800 visualization Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/06—Phosphorus compounds without P—C bonds
- C07F9/08—Esters of oxyacids of phosphorus
- C07F9/09—Esters of phosphoric acids
- C07F9/095—Compounds containing the structure P(=O)-O-acyl, P(=O)-O-heteroatom, P(=O)-O-CN
- C07F9/096—Compounds containing the structure P(=O)-O-C(=X)- (X = O, S, Se)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
- C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
- C07C323/51—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
- C07C323/57—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being further substituted by nitrogen atoms, not being part of nitro or nitroso groups
- C07C323/58—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being further substituted by nitrogen atoms, not being part of nitro or nitroso groups with amino groups bound to the carbon skeleton
- C07C323/59—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being further substituted by nitrogen atoms, not being part of nitro or nitroso groups with amino groups bound to the carbon skeleton with acylated amino groups bound to the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/795—Porphyrin- or corrin-ring-containing peptides
- C07K14/805—Haemoglobins; Myoglobins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Molecular Biology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Peptides Or Proteins (AREA)
Abstract
Hemoglobin cross-linked with disulfide linkages at sites external to the native globin chains is prepared by reacting hemoglobin with site-directed reagents exemplified by N,N'-bis Cbz-cysteinyl bis (methyl phosphate). Reaction with deoxy hemoglobin produces two main products: cross-linked hemoglobin as the bis cysteinyl amide of the .epsilon.-amino group of the side chain of Lys-82 of the two .beta. subunits, and modified but non-cross-linked hemoglobin that has each of the same amino groups modified as the cysteinyl amide. Disulfide cross-linked hemoglobin has a variety of uses. The disulfide bonds can be cleaved with reducing agents to give terminal sulfhydryl groups, useful in chemical bonding to sulfhydryl group-containing biochemically active compounds to form conjugates thereof for drug delivery. Hemoglobin crosslinked through disulfide bonds can be formed from the sulfhydryl group terminated reduction products, for use as a hemoglobin-based oxygen carrier.
Description
HEMOGLOBIN WITH CHEMICALLY INTRODUCED
DISULFIDE CROSS-LINKS AND PREPARATION THEREOF
FIELD OF THE INVENTION
This invention relates to protein modification, and to processes and reagents useful therein. It also relates to novel, modified proteins, and to reactions of them to form conjugates with various biochemically active molecules and groups. More specifically, the invention relates to reagents for modifying hemoglobin, including cross-linking of hemoglobin, modified hemoglobins produced using the reagents, and use of the modified hemoglobin for conjugation of biomolecules thereto.
BACKGROUND OF THE INVENTION
Modified human hemoglobin is a central component of most materials that have been developed as potential blood substitutes . Cross-linking, either by chemical modification or genetic engineering, is necessary to stabilize the tetrameric protein and counteract its tendency to dissociate into a~i sub-units. As blood substitutes, cross-linked hemoglobins have to be tolerated in large quantities . Hemoglobin-based oxygen carriers (HBOCs) also provide a possible means of delivery of therapeutically active substances to sites of the body, since HBOCs are a circulatory, biocompatible medium which perfuse tissues and organs of the body. Their globin chains have many chemical sites theoretically capable of bonding to a therapeutic substance to act as a carrier therefor. Any such chemical bonding will, however, effect modification of the globin chains, and care must be taken to ensure that the modification does not have an adverse effect on other properties of the HBOC.
The functionality introduced by cross-linking hemoglobin also has the potential for creating sites for bioconjugation.
BRIEF REFERENCE TO THE PRIOR ART
U.S. Patent 5,399.671 Klu~er and Sony, issued March 21, 1995, teaches cross-linking of hemoglobin with a trifunctional reagent in which only two of the functionalities react with the hemoglobin to effect cross-linking, leaving one functionality on the cross-linker residue available for reaction with an exogenous nucleophile.
International Publication W093/08842 (PCTlUS92/097131 Somato~~en Inc. (Anderson et alb describes methods and compositions for delivering drugs to the body by binding them to hemoglobin, utilizing cysteine units of the native globin chains of hemoglobin ("internal sites") as the binding sites.
Many natural proteins contain internal disulfide bonds, naturally formed and imparting stability to the protein. These are formed between cysteine units of the peptide chains, and may stabilize the protein in a naturally folded condition. Albumin, for example, has cysteine residues which participate in disulfide bonds in naturally folded albumin.
Hemoglobin, although containing one or two cysteine residues in the globin chains of its sub-units, does not naturally include disulfide cross-links to confer stability on the tetramer.
SUMMARY OF THE INVENTION
. It is an object of the present invention to provide novel reagents for modifying proteins such as hemoglobin.
It is a fiuther object to provide novel modified hemoglobin capable of bioconjugation to biochemically active compounds.
It is a further object of the invention to provide tetrameric hemoglobin stabilized by disulfide cross-links.
The present invention provides, from one aspect, modifying reagents for proteins such as hemoglobin, containing disulfide bonds. The reagents have functionalities which react site-specifically with globin chains of the hemoglobin either to effect cross-linking, while leaving the disulfide bonds intact, as part of the cross-link group, or to provide novel complexes having side chains containing disulfide groups. In either case, the products can be reacted with reducing agents to cleave the disulfide bond and to provide modified hemoglobin products with terminal sulfhydryl groups, available for conjugation to therapeutically active compounds, e:g. biomolecules. In addition, the products with terminal sulthydryl groups can be oxidized to re-form the disulfide bonds and hence produce cross-linked hemoglobin.
DISULFIDE CROSS-LINKS AND PREPARATION THEREOF
FIELD OF THE INVENTION
This invention relates to protein modification, and to processes and reagents useful therein. It also relates to novel, modified proteins, and to reactions of them to form conjugates with various biochemically active molecules and groups. More specifically, the invention relates to reagents for modifying hemoglobin, including cross-linking of hemoglobin, modified hemoglobins produced using the reagents, and use of the modified hemoglobin for conjugation of biomolecules thereto.
BACKGROUND OF THE INVENTION
Modified human hemoglobin is a central component of most materials that have been developed as potential blood substitutes . Cross-linking, either by chemical modification or genetic engineering, is necessary to stabilize the tetrameric protein and counteract its tendency to dissociate into a~i sub-units. As blood substitutes, cross-linked hemoglobins have to be tolerated in large quantities . Hemoglobin-based oxygen carriers (HBOCs) also provide a possible means of delivery of therapeutically active substances to sites of the body, since HBOCs are a circulatory, biocompatible medium which perfuse tissues and organs of the body. Their globin chains have many chemical sites theoretically capable of bonding to a therapeutic substance to act as a carrier therefor. Any such chemical bonding will, however, effect modification of the globin chains, and care must be taken to ensure that the modification does not have an adverse effect on other properties of the HBOC.
The functionality introduced by cross-linking hemoglobin also has the potential for creating sites for bioconjugation.
BRIEF REFERENCE TO THE PRIOR ART
U.S. Patent 5,399.671 Klu~er and Sony, issued March 21, 1995, teaches cross-linking of hemoglobin with a trifunctional reagent in which only two of the functionalities react with the hemoglobin to effect cross-linking, leaving one functionality on the cross-linker residue available for reaction with an exogenous nucleophile.
International Publication W093/08842 (PCTlUS92/097131 Somato~~en Inc. (Anderson et alb describes methods and compositions for delivering drugs to the body by binding them to hemoglobin, utilizing cysteine units of the native globin chains of hemoglobin ("internal sites") as the binding sites.
Many natural proteins contain internal disulfide bonds, naturally formed and imparting stability to the protein. These are formed between cysteine units of the peptide chains, and may stabilize the protein in a naturally folded condition. Albumin, for example, has cysteine residues which participate in disulfide bonds in naturally folded albumin.
Hemoglobin, although containing one or two cysteine residues in the globin chains of its sub-units, does not naturally include disulfide cross-links to confer stability on the tetramer.
SUMMARY OF THE INVENTION
. It is an object of the present invention to provide novel reagents for modifying proteins such as hemoglobin.
It is a fiuther object to provide novel modified hemoglobin capable of bioconjugation to biochemically active compounds.
It is a further object of the invention to provide tetrameric hemoglobin stabilized by disulfide cross-links.
The present invention provides, from one aspect, modifying reagents for proteins such as hemoglobin, containing disulfide bonds. The reagents have functionalities which react site-specifically with globin chains of the hemoglobin either to effect cross-linking, while leaving the disulfide bonds intact, as part of the cross-link group, or to provide novel complexes having side chains containing disulfide groups. In either case, the products can be reacted with reducing agents to cleave the disulfide bond and to provide modified hemoglobin products with terminal sulfhydryl groups, available for conjugation to therapeutically active compounds, e:g. biomolecules. In addition, the products with terminal sulthydryl groups can be oxidized to re-form the disulfide bonds and hence produce cross-linked hemoglobin.
The modified reagents of the present invention are derivatives of cystine, in which the free amino groups are derivatized with bulky protectaat groups such as carbobenzoxy, and in which the carboxylic acid groups are esterified with amino-reactive leaving groups, such as methylphosphate and electronegatively substituted phenyl groups. The reagents correspond to the general formula A:
R. O. CO-CH-CH2-S-S-CH2-CH-CO.O-R
CA) NH.R~ NH.R~
where R represents an amino-reactive leaving group selected from lower alkyl phosphate and electronegatively substituted phenyl, and R' represents a bulky, N-protectant group such as carbobenzoxy, benzenesulfonyl, toluenesulfonyl, t-butyloxycarbonyl, fluorene-methoxycarbonyl, etc., as commonly used in protein chemistry. The reagents have a sufficiently short chemical chain length between respective amino-reactive leaving groups that they do not effect cross-linking between different hemoglobin tetramers to form 128 kd products (intermolecular cross-linking), only reaction with different (3-sub-units of the same tetramer.
The invention also provides a process of modifying hemoglobin which comprises reacting hemoglobin, in its deoxy state, with a modifying reagent of formula A give above. The acylation reaction occurs at amino acid residues in the diphosphoglycerate (DPG) binding site of the hemoglobin, specifically at the E-amino groups of lys-82 in the S
~3-subunits, and produces some cross-linked product of the general formula B:
Lys-(38~-NH.co . CH- CAL- S
r d, a NMR' Lys_(~'82-NW-Cv.CN ~CN1'S
I
NHft along with modified products having disulfide linkages in side groups, of general formula C:
(C) I '' NNR' t~NfZ~
In the general formulae, the symbol ~ ~,~ represents tetrameric hemoglobin. The group -Lys-~3-82-NH represents the lysine residues at position 82 on the respective ~i-globin chains of hemoglobin L~S._ ~8~.-IVN.Cp, iH. CNl_$-S-GNz. iN _ CDOH
NHR' NH2~
y, ~yS-(~ ~Z-NI-~.CO.CH.CN . S-S-Cl~ .CI-~- COON
with linkage to the side groups through the E-amino group thereof.
wo ~rr~o6s rcric~9aromo Another aspect of the invention is the modified hemoglobins so produced, which are novel products, represented by formulae B, and C
given above.
A further aspect is the process of preparing modified hemoglobin having side chains with terminal sulfhydryl groups bonded to ~i-iys-82 and/or Vii'-lys-82, which comprises subjecting modified hemoglobins of formulae B and/or C, to reduction so as to effect reductive cleavage of the disulfide bond. The modified hemoglobin so formed, of general formula D:
NN. ~o . ~ N - t NL- S H
d, ~ a NHR, rvN. co.cN-c~ly-$H (D) rt H R
is then reactable with any of a wide variety of biochemically active compounds, to form a conjugate administrable to a patient as a means for delivering the biochemically active compound to the patient.
Yet another aspect of the present invention is a process for preparing cross-linked tetrameric hemoglobin having cross-links between respective lysine-82 groups of the ~i-globin chains thereof, which comprises oxidizing the product of formula D given above, to re-form the disulfide bond. The cross-linked product so formed, which is the product of formula B given above, also constitutes an aspect of the present invention. This product B is a hemoglobin tetramer stabilized with disulfide cross-links to inhibit dissociation into dimeric sub-units. The disulfide cross-link resembles the natural disulfide cross-link present in many other naturally occurring proteins, and effecting a degree of conformational stability thereon.
The reagents of the present invention do not react with the N-terminal amino groups (Val-1) as do reagents that are bis methyl phosphates derived from simple dicarboxylic acids. It is likely that the bulk of the N-protected amino group in the reagents produces additional selectivity based on steric effects.
X-ray crystallographic structures of deoxy hemoglobin reveal that the (3-Lys-82 E-amino groups are outside the protein at the interface between the DPG-binding site and the surrounding solution . By contrast, the oc-amino group of the N-terminal (3-Val-1 is further within the DPG-binding site. Modeling of the reagent into the structure of deoxy hemoglobin suggests that the reagents bind to the DPG site at the solution interface, limiting reaction to the lysine residues. The steric bulk of two Cbz amino-protecting groups in the reagents provides selectivity beyond that found with acyl phosphate monoesters toward amino groups in hemoglobin.
BRIEF DESCRIPTION OF THE DRAWINGS
Figure 1 is an anionic exchange HPLC chromatogram of the reaction mixture resulting from Example 2 below, run under conditions which do not dissociate uncross-linked hemoglobin tetramers;
Figure 2 is an HPLC chromatogram of the separated globin chains from the reaction mixture in Example 2 below;
Figure 3 is a chromatogram of separated globin chains from Example 3 below, taken at an early stage of the reaction; and Figure 4 is an HPLC chromatogram of the products of Example 4 below, taken at an early stage of the reaction.
DESCRIPTION OF THE PREFERRED EMBODIIVVIENTS
The preferred cross-linking reagent according to the present invention is N,N'-bis-carbobenzoxy-cysteinyl-bis-(methylphosphate), sodium salt of formula I:
O O O O
I l ll ~I
Na+ 'O-l~~ O-C-CH-CH2-S-S-CH2-CH-C-O-P-O- +Na OCH3 NH I~ H OCH3 (I) C=O C=O
I I
O. CH2. C6H5 O. CH2. C6H5 This new reagent is referred to hereinafter as "ZCMP" . It be prepared from the reaction of the bis-acid chloride of N-protected cystine with dimethylphosphate followed by O-demethylation with methyl iodide in acetone. ZCMP is an example of a compound of general formula A
above in which R represents methylphosphate and R' represents carbobenzoxy.
Other preferred reagents according to the invention are those in which R is an electronegatively substituted phenyl group of general formula pZo where Z represents one or more independently selected electronegative groups having positive Hamnnet sigma values, and n is an integer from 1-5.
Examples of suitable groups Z are acetanudo (at the ortho or meta positions), acetoxy, acetyl, carbomethoxy, carboxy, halo, cyano, ethoxy (at the ortho or meta positions), hydroxy (at the ortho or meta positions), vitro, phenyl, trifluoromethyl and trimethylammonio. Preferred as substituent group Z are carboxyl, phosphonate, sulfonate, sulfate, phosphonate and halogen. Two or three such substituents are preferred, and especially cases where one of the substituents is carboxyl. When only one such substituent is present, it is preferred that it is located in the position orkho to the ester linkage to the aromatic nucleus. Most preferred for group R according to this embodiment is dibromosalicylate.
The hemoglobin which is used in the process of the present invention is preferably human hemoglobin, although the invention is applicable to other types of hemoglobin also, such as bovine hemoglobin and porcine hemoglobin and other animal hemoglobins. The source of the WO ~~~ PCT/CA98/01020 hemoglobin is normally red blood cells, although hemoglobin obtained by genetic engineering, recombinant techniques is also useful.
The cross-linked hemoglobin so formed, with the disulfide bonds intact, can be safely administered to human patients as a hemoglobin-based oxygen Garner.
Alternatively and preferably, however, the cross-linked hemoglobin is subjected to reductive cleavage so as to cleave the disulfide bonds, and form terminal sulfliydryl groups on the side chains bonded to a specific site of a specific globin chain. The cleaved product is then reacted with a biochemical molecule, utilizing the terminal sulfhydryl group, and administered to the body to act as a delivery medium for delivery of the biochemically active compound to the body.
The attachment of the biochemically active compound to the modified hemoglobin according to the present invention utilizes sulfhydryl bonds, located at the terminus of side chains remote from the point of attachment to the globin chains of the hemoglobin, and hence available for ready reaction with biochemically active compounds. The preferred linkage is a disulfide link, formed from the sulfhydryl group of the hemoglobin side chain and a sulfhydryl group of the biochemically active compound, or a sulfhydryl group of a linker or spacer molecule to which the biochemically active compound is in turn linked. A disulfide bond is slowly reduced by reducing agents present in human serum, so that a biochemically active compound so linked to the hemoglobin is slowly released into the blood stream. Reagents and conditions for formation of wo ~n3o6s rcric~9s~omo m disulfide bonds are well known in the art. Release of the biochemically active molecule from the hemoglobin, in order for it to exhibit its biochemical activity, is not necessary, in many cases. The conjugate with hemoglobin may exhibit the biochemical activity of the conjugant.
Biochemically active molecules which include sulfhydryl groups in their native structure include a wide variety of proteinaceous compounds which incorporate cysteine residues. These include atrial natriurectic factor (ANF), antithrombotic peptides such as RGDW; antiproliferatives or antimetastics such as RGD polymers or analogues thereof, and GRDGDS
or analogues thereof; antihypertensives-renin inhibitors such as Boc-HPFHL-CH(OH)-CH2-VIH or analogues thereof; human growth hormone releasing factor analogues; anorexigenics; vasoconstrictors such as arginine vasopressin; vasodilators such as angiotensin converting enzyme inhibitors; and anti-AIDS drugs such as HIV protease inhibitors.
Other sulthydryl group containing therapeutically active compounds which can be conjugated to the modified hemoglobin of the invention include captopril ( 1-(3-mercapto-2-methyl-1-oxopropyl)-L-proline).
The reactions of ZCNiP with hemoglobin follow the patterns of other anionic electrophiles. The reagent reacts efficiently only with the deoxy form. Its acylating reaction occurs at residues in the DPG binding site at the E-ariiino groups of Lys-82 in the (3 subunits.
The reaction of ZCMP with carbonmonoxy hemoglobin gives only a very small amount of product under the conditions that extensively modify the deoxy form. The product that does form is not cross-linked.
This result is consistent with the conformational change of hemoglobin in going from the R state to the T state. When deoxy hemoglobin binds to ligands such as oxygen and carbon monoxide, the extensive quaternary structural change leads to contraction of the DPG binding site. As a consequence, the DPG binding site is not large enough to be accessed by such a bulky reagent.
The disulfides of the two [3-chain-modified hemoglobins, compounds B and C above, show different reactivity with mild reducing agents such as (3-mercaptoethanol. With this reagent, the linear disulfide compound C is reduced to form compounds with terminal sulfhydryl groups (compound D) whereas the cross-linked disulfide B remains largely unaffected. The reaction mechanism and accessibility of the S-S bonds of modified hemoglobins explains this difference. Reduction of a disulfide by thiol reagents proceeds in two steps. A mixed disulfide of the cleaved disulfide and mercaptoethanol is an intermediate. In the thiol-disulfide exchange process, a large excess of the reagent is required to drive the reaction to completion.
For the cysteinyl hemoglobin with no cross-links, one end of the reagent is attached to J3Lys-82. The unreacted portion of the large, hydrophilic reagent is probably out of the DPG binding site. Therefore, the disulfide is~ accessible to 2-mercaptoethanol. On the other hand, if the (3 subunits of hemoglobin are cross-linked as the bis cysteinyl derivative, the S-S bond within the DPG cleft becomes less accessible to the thiol reagent. The DPG binding site protects the disulfide from reduction, and the reaction of that disulfide bond with 2-mercaptoethanol is blocked.
The S-S bond of the cross-linked hemoglobin is cleaved with more effective reducing reagents such as dithiothreitol (DTT). When dithiothreitol is used to reduce the S-S bond, the first step is also a thiol-disulfide exchange as with 2-mercaptoethanol. However, once the intermediate is formed, a second molecule of reagent does not participate in the reaction. Instead, an intramolecular reaction can occur, leading to the formation of the stable cyclic disulfide of DTT. The intramolecular process has a large entropic advantage in its favor. Since the cross-linked hemoglobin was reduced without the addition of denaturing reagents, the S-S bond is near the outside of the DPG cleft of the cross-linked hemoglobin and is exposed to solvent.
In any event, the end product of reduction of both compound B and compound C is a modified hemoglobin with terminal sulfhydryl (thiol) groups, of general formula D above.
Depending upon the choice of protectant group R' in the modifying reagent, it may be desirable to remove it prior to administering products of the present invention to a patient. This will depend largely on toxicity considerations. Removal of the protectant groups can be accomplished by standard methods employed in peptide chemistry.
The oxidation of thiols to disulfides by oxygen normally proceeds only in the presence of catalytic quantities of metal ions such as iron and copper. The rate of the oxidation of thiols in the same molecule depends on the distance between the thiol groups. In the present case, it has been found that the modified hemoglobin with two free sulfhydryl groups attached at (3-Lys-82 is oxidized spontaneously by atmospheric oxygen, quantitatively producing the cross-linked tetramer. It is possible that the iron of the heme facilitates the reaction, especially that which is present as Fe(III) met-hemoglobin. The sulfliydryl groups produced by reduction iii the process of the present invention remain in close spatial proximity in order to form the disulfide bond between subunits by oxidation. Cleavage of the disulfide at each'site, followed by oxidation permits spontaneous formation of the cross-link between dimers. This produces a much higher yield of cross-linked materials and provides an added benefit of the use of such reagents. Accordingly, a preferred process for making an HBOC according to the present invention comprises reacting human deoxy hemoglobin with a disulfide group containing protein modifying reagent as previously described, to form a mixture of cross-linked and non-cross-linked modified hemoglobin (products B and C) above, subjecting the mixture to reductive cleavage of the disulfide bonds to form a modified hemoglobin of general formula D, and then oxidizing this modified hemoglobin to form disulfide cross-linked hemoglobin. Such a process is capable of producing substantially quantitative yields of cross-linked hemoglobin.
The introduction of specific chemical alterations at defined sites within a protein is complementary to methods based on genetic engineering. The design of the modifying reagent ZCNiP of the preferred embodiment of the invention permits site selection based on charge and steric factors. The fact that ZCMP is an amino acid derivative permits chemical techniques to be used that are extended from the chemistry of peptide formation. A wide variety of side chains, as well as longer peptides for conjugation, can be implemented in combination with the convenient methods developed for producing the mixed phosphate-amino acid anhydride.
The use of the disulfide-based reagent in the present study adds fiuther possibilities for applications of cross-linking by converting sites that contain lysyl side chains into those connected as disulfides and also, by reduction, to sites for bioconjugation.
The invention is further described, for illustrative purposes, in the following specific examples.
EXPERIMENTAL PROCEDURES
General Methods. Water was doubly distilled and deionized. All pH
measurements were standardized against calibrated buffers using a combination glass electrode. Molecular mechanics was employed to obtain preferred conformations based on several initially estimated structures of bis(N-Cbz)-cysteinyl bis(methyl phosphate). The coordinates of deoxy hemoglobin of Fermi and Perutz (Re f. 1, infra) from the Brookhaven protein database were used for visualization of the structure of the protein.
Melting points were obtained in a calibrated oil bath apparatus. Proton NMR spectra were recorded at 200 MHz and 300 MHz with chemical shifts reported relative to TMS or DSS. '3C NMR spectra were recorded WO 99/23065 PCT/CA98/IIlOZO
on the same instruments at 50 MHz and 75 MHz. Carbon chemical shims were measured relative to the chloroform-d with TMS at 0. 31P NMR
spectra were recorded at 120 MHz and chemical shifts are relative to 85%
phosphoric acid in water. Infrared spectra were recorded on a FT-IR
spectrometer in KBr pellets. Mass spectra were recorded by electron-impact (EI) or fast atom bombardment ionization (FAB). The Mass Spectroscopy Laboratory, Department of Medical Genetics, University of Toronto provided electrospray ionization mass spectra. Chemical modification of hemoglobin and analysis followed general procedures as reported for related materials. (Refs. 2 and 3, infi-a) Examule 1- Synthesis of N.N'-bis-Cbz-cystein l~bis ,(,Sodium MethXt Phosphate) (ZCMP,~
N,N'-bis-Cbz-cysteinyl dichloride (1.0 g, 1.8 mmol) and sodium dimethyl phosphate (0.54g, 3.6 mmol; from trimethyl phosphate and one equivalent of sodium iodide in dry acetone) were suspended in 30 mL dry tetrahydrofuran at 0° C under nitrogen and stirred for 1 hr. The resulting precipitate of sodium chloride was removed by filtration.
The filtrate contained the reaction product N-Cbz-cysteinyl bis-dimethyl phosphate, 2 Sodium iodide (2.2 g, 14.6 mmol) was added to the filtrate to replace one methyl group at each phosphate with sodium.
The mixture was stirred at S° C for 48 hr. Solvent was removed by rotary evaporation. The resulting solid was crystallized from acetone-ether, producing an off white powder. This was collected and washed three times with acetonitrile. The powder was dried in vacuum to give 1.0 g (1.35 mmol, 74% yield) N-Cbz-cysteinyl bis (sodium methyl phosphate) (ZCMP) as a white solid, mp > 200 °C. IR (KBr) C~ 1675 cni 1, 1695 crri'; 1H NMR (200 MHz, D20, 87.26 {s, lOH, 2C6H5), 4.88 (s, 4H, 20CH2Ph), 4.44 (m, 4H, NH and NCH), 3.45 (dd, 6H, JP-H = 11.5 Hz, 20CH3), 2.70-3.25 (m, 4H, SCH2); 13C NMR (121 MHz, D20) 8168.3 (d, JP-C = 9.7 Hz, P-O-C=O), 157.29 (C=O), 135.9, 128.4, 128.3, 127.7, 67.1, 53.9 (d, JP-C = 6.4 Hz, OCH3), 37.8; 31P NMR (121 MHz, D20) 8-5.4 (q, JP-H = 11.3 Hz); FAB mass (-, glycerol) 717 (38.0, M-Na+).
Example 2 - Preparation of deoxy hemoglobin and its reaction with ZCMP
A solution of hemoglobin (80 mg/mL in 6 mL O.1M pH 8 MOPS) in a SO-mL rb flask was immersed in an ice-water mixture. This was connected to a rotating reactor containing tubes for inflow and outflow of gasses. Humidified oxygen was then passed through the solution for one hr with the flask illuminated by a tungsten lamp. The resulting oxy hemoglobin was converted to the deoxy form by passing a stream of humidified nitrogen over the rotating solution for 3 hr at 37°C.
A solution of ZCMP was added over 15 min to a solution of hemoglobin in buffer {0.5 mM) so that the final conc. of ZCMP in the mixture was 0.7 mM and that of hemoglobin was 0.25 mM (0.1 M MOPS, pH 8.0). Other buffering agents of the kind known as Good buffers may be used in lieu of MOPS, e.g. sodium borate, but more chemically reactive conventional buffers such as Tris and bisTris will react adversely with ZCMP or other protein-modifying agents according to the invention.
The buffered hemoglobin solution was kept at 37 °C. For reactions with deoxy hemoglobin, the reagent was degassed and was introduced under nitrogen. The reaction was carried out under flowing nitrogen. For reactions with carbonmonoxy hemoglobin, the reaction solution was saturated initially with carbon monoxide. After the ZCMP
was added to the solution of hemoglobin, the reaction was continued for 2 hr. The flask was then disconnected from the rotating reactor and carbon monoxide was introduced. The solution was passed through a column of Sephadex G-25 equilibrated with 0.1 M pH 8 MOPS to remove excess reagent. The resulting material (ca. 20 mL) was collected in a vial.
Analysis of the resulting modified hemoglobin was done with a combination of reversed-phase HPLC and ion exchange HPLC following previously reported procedures. (2) Product Analysis Extent of cross-linking. A sample of the reaction product (1.0 mL) was passed through a gel filtration column of Sephadex-100 (superfine) that had been equilibrated with 1.0 M magnesium chloride.
Under these conditions hemoglobin that is not cross-linked dissociates into a[3 dimers. The dimers elute more slowly than do cross-linked tetrameric species. The extent of cross-linking of globin chains was also determined by polyacrylarnide gel electrophoresis in the presence of sodium dodecyl sulfate (SDS PAGE ) on Mini-Protean II Ready Gels (12%
polyacrylamide, 0.375 M Tris-HCI, pH 8.8) as reported previously. (Ref.
4, infra) The hemoglobins and globins from HPLC preparations were WO 99!13065 PCT/CA98/01020 denatured in 0.065 M Tris-HC1, pH 6.8, 2% SDS, 10-v/v glycerol.
Approximately 20 p,g of protein was applied to each lane of the gel and processed at 200 V for 1 hr. Protein bands on the gel were stained with Coomassie brilliant blue R-250.
Analytical and preparative separation of globin chains.
Modified hemoglobins were separated as intact tetramers by anion exchange HPLC on a SynChropak AX300 column (250 x 4.6 mm) using a mixture of 0.025 M bis-tris and 0.025 M tris with gradients starting from pH 8.5 to pH 6.7. The effluent was monitored at 540 nm. Heme and globin chains were separated by reversed phase HPLC using 330 A pore C4 Vydac columns (250 x 4.6 mm for analytical and 250 x 12 mm for preparative). Developers contained 0.1 % trifluoroacetic acid and various gradients of acetonitrile starting at 20% and ending at 60%. The effluent was monitored at 220 nm. Globin chains were recovered from the effluent by lyophilization.
Digestion of globin chains. Globin chains were dissolved in 8 M urea to increase susceptibility to hydrolysis and kept at room temperature for 2-4 hr. The solution was then diluted to 2 M urea with 80 mM ammonium bicarbonate buffer at pH 8.5. Trypsin (2% of total protein) was added, and the solution was digested for 24 hr at room temperature.
The hydrolysate was heated in boiling water for 2 min, diluted to 1 M urea with 80 mM ammonium bicarbonate buffer, and further digested with endoproteinase Glu-C (1% of total protein) for another 72 hr at room temperature. The hydrolysates were filtered before injection into the HPLC.
Chromatography of peptides. Peptide fragments were separated by analytical HPLC using reversed phase C 18 columns (3 .9 x 300 nun). Developers consisted of 0.1% trifluoroacetic acid in water with gradients of acetonitrile from 0 to 100% over ca 2 hr. The HPLC effluent was monitored at 214 and 280 nm.
Combination of ZCMP with deoxy hemoglobin (3:1 reagent:
protein) in aqueous buffer as described above produced a set of modified hemoglobins. Under the same conditions, carbonmonoxy hemoglobin underwent very little reaction. The resulting proteins from reaction of deoxy hemoglobin and ZCMP were separated by anion-ion exchange HPLC (AX-300). Enzymic digestion and mass spectral analysis were used to determine the sites of the modifications resulting from reaction with ZCMP. The HPLC chromatogram of the reaction mixture containing intact tetramers is presented as Figure I of the accompanying drawings and shows that the solution contained only a small amount of unreacted hemoglobin (aa(3(3) along with two major peaks corresponding to modified tetramers.
Two minor products elute after the major constituents.
Further analysis of the components of the modified proteins by reversed-phase HPLC indicates that the two major products have native a chains along with modified (3 chains (determined by comparison with unmodified protein).
Figure 2 shows the results of HPLC analysis of the reaction mixture under conditions that separate the globin chains. Structural analysis of each component (from digestion, SDS-PAGE, and peptide analysis) indicates that there are two (3-modified tetrameric products.
Peaks 1 and 2 correspond to modified (3 subunits. The first peak is material that is modified by reaction with ZCMP without cross-linking (the cysteinyl amide, compound corresponding to general formula C above).
The second contains the two subunits cross-linked as the cysteinyl bis amide (Compound B above). Enzylnic digestion followed by peptide analysis reveals that in both peaks, modification is at the E-amino group of lysine-82 of the ~i subunits. Two minor products, peaks 3 and 4, were shown by a similar analysis to be modified a subunits. Ion-spray mass spectral analysis (Ref. 5, infra) of material from reversed-phase HPLC
gives the molecular weight of the cross-linked (3 chains as 32208, consistent with two (3 chains linked as the N,N'-CBZ-cysteinyl bis-amide.
The peaks from the material that is not cross-linked are consistent with a species in which an amide has formed from reaction of ZCMP with the lysyl-82 E-amino group while the second acyl group of the reagent has undergone hydrolysis (Table 1).
WO 99/23065 PCT/CA98/OlOZO
TABLE 1 - Ion-sprays spectral parent peaks of modified g~obin chains obtained from reaction of deoxy hemoglobin with ZCMP
GLOBIN CHAIN OF FOUND EXPECTED
HEMOGLOBIN (Molecular weight) (Molecular weight) Unmodified (3- 15868.80 ~ 1.50 15867 subunits Modified ~i-subunits16359.01 t 1.50 16357 Cross-linked ~3- 32207.78 ~ 1.87 32206 subunits Unmodified a- 15127.24 t 1.55 15126 subunits Modified a-subunits15616.19 ~ 1.55 15616 Where a cross-linked hemoglobin of the kind of Compound B
according to the invention is not to be subjected to reductive cleavage of its disulfide crosslinks but, rather, is to be used as tetrameric (e.g., as an HOBC), the material may be reacted fiuther with an a cross-linker such as 3,5 DBSF. Since ZCMP reacts with hemoglobin primarily at the ~3 chains and 3,5 DPSF leads to cross-linking at the a Lys 99 positions, the result is a doubly cross-linked (or doubly-modified) hemoglobin. As reported previously by Kluger, et al. (Ref. 3, infra), if the DPG site is blocked (as it would be, given a Cbz-cysteinyl cross-link between the (3Lys 82 residues) then 3,5 DBSF cross-links only at the aLys 99 residues. Unintended cleavage of the Cbz-cysteinyl link in such a doubly cross-linked hemoglobin would still leave a fumaryl link between the a chains to keep the tetramer together.
Example 3 - Reduction of the disulfide of bis-c stein3rl deox~r hemoglobin with 2-mercaotoethanol.
2-Mercaptoethanol (0.018 g) was dissolved in 1 mL 0.1 M
pH 8.0 MOPS. 0.1 mL of the solution was added to one mL of a solution of the modified hemoglobins from the reaction of deoxy hemoglobin with ZCMP. The reaction mixture was stirred at 5 °C. Samples were analyzed by reversed-phase HPLC.
Progress of the cleavage reaction was followed by reversed-phase HPLC. When the modified hemoglobins from the reaction of ZCMP
with deoxy hemoglobin were treated with a 20 fold excess of 2-mercaptoethanol for 1 hr, the modified but not cross-linked hemoglobin was reduced to yield t-wo products in approximately 1:1 ratio (Figure 3 shows a chromatogram from analysis early in the course of the reaction).
As peak 1 disappeared, two new peaks {peak 5 and 6) appeared with shorter retention times. The structures of these products were established by electrospray ionization mass spectral analysis. Peak 5 is the reduced (3 chain corresponding to the desired product that results from the cleavage of the disulfide bonds. The reaction of 2-mercaptoethanol with modified (but not cross=linked hemoglobin is summarized in Scheme 1. The formation of a mixed disulfide intermediate and cleavage.occurs only with material that is not cross-linked by 1. Peak 6 is the mixed disulfide intermediate (of mercaptoethanol and modified and hemoglobin), with a parent mass of 16178 ~ 2 (calcd 16180). Such a mixed disulfide is consistent with formation of intermediates by this reagent. (21,22). Thus, the possible products are reduced of cross-linked hemoglobin and two hemoglobins with mixed disulfides. However, the reaction of the disulfide of cross-linked hemoglobin with 2-mercaptoethanol proceeded very slowly under the same conditions. Peak 2, corresponding to cross-linked hemoglobin, did not decrease. The calculated mass of the modified ~3 chain with a cleaved sidulfide, a cysteinyl amide of the ~i subunit of hemoglobin, is 16,105; found: 16106.71.4.
The modified protein mixture from the reaction of ZCMP
with deoxy hemoglobin followed by treatment with an excess of 2-mercaptoethanol for a few minutes was analyzed as follows. Mass spectra reveal that Peak 5 is the (3 chain corresponding to the product that results from the cleavage of the disulfide bonds derived from the protein modified by ZCMP.
s-s sH SH
« p « HSCH2CHZOH « p « HSCH2CH20H
P «
s-s P
SSCHiCHzOH SH
« ~ « ~ HSCHZCH20H
- SLOW
a Examule 4 - Reduction of modified hemoglobin with dithiothreitol and subsequent re-oxidation Dithiothreitol (DTT) (0.073 g, four equivalents) was dissolved in 1 mL 0.1 M pH 8.0 MOPS. 0.01 mL of the DTT solution was added to 1 mL of the solution of modified hemoglobins from the reaction of deoxy hemoglobin with ZCMP. The reaction mixture was stirred at 5 °C and the sample analyzed by reversed-phase HPLC. After 15 min, the product was passed through a column of Sephadex G-25 equilibrated with 0.1 M pH 8.0 MOPS to remove excess dithiothreitol. The sample was collected and analyzed again by reversed-phase HPLC.
Dithiothreitol (DTT) is a more effective reducing agent than 2-mercaptoethanol. In this experiment with DTT, all disulfide bonds were cleaved within 15 minutes. The reversed phase HPLC showed none of the original peaks derived from the (3-subunits. There was a single product peak at the position of the cysteinyl derivative of the ~i subunit. This is the same species generated in the reaction with 2-mercaptoethanol and with the same mass (16,105). The bis cysteinyl amide (aa~i-Lys-82-cys-S-S-cys-(Lys-82)-(3) is cleaved at the disulfide.
Figure 4 shows the reversed-phase HPLC chromatogram of the products from an early stage in the reaction with DTT (showing some remaining unreacted [3 subunits are present). The peaks are numbered as in Figure 3. The bis sulfide now appears as peak 5 but, as required, the intermediate from 2-mercaptoethnaol (peak 6) is not present. The reaction pattern with DTT is summarized in Scheme 2.
S--S SH
DTT
a a a a s-s p sH
SH
a ~ a S DTT
I ~ a a S
SH
Gel filtration chromatography was used to separate modified protein from excess DTT after reduction. The product in the presence of air and the absence of DTT is rapidly oxidized to produce once again aa(3-Lys-82(E-NH-cys-S-S-cys-( E-NH-Lys-82)(3 quantitatively. HPLC
reverse phase analysis after 15 minutes reveals the decrease of peak 5 (modified, not cross-linked) and a large increase in peak 2, that of the cross-linked species. Re-treatment of the protein solution with DTT once again gives the disulfide-cleaved products exclusively (HPLC analysis).
Therefore, the reduction-oxidation procedure is an efficient way to convert material that is not cross-linked into cross-linked material (Scheme 3).
Scheme 3 SH
a~~
a a ~a SH
SH
a wo ~n3o6s ~cTicw9sroiozo References (1) Fermi, G. and Perutz M.F. {1984) The crystal structure of human deoxyhaemoglobin at 1.74 Angstroms resolution. J. Mol.
Biol., 175, 159-174.
(2) Jones, R.T. (1994) Structural characterization of modified hemoglobins. Methods in Enzymology, 231, 322-343.
(3) Jones, R.T., Shih D.T., Fujita T.S., Song Y., Xiao H., Head C.
and Kluger R. (1996) A doubly cross-linked human hemoglobin.
Effects of crosslinks between different subunits. J. Biol. Chem., 271, 675-680.
(4) Kluger, R. and Song Y. (1994) Changing a protein into a generalized acylating reagent. J. Org. Chem., 59, 733-736.
(5) Fenn, J.B., Mann M., Meng C.K., Wong S.F. and Whitehouse C.M. (1989) Electrospray ionization for mass spectrometry of large molecules. Science, 246, 64-71.
R. O. CO-CH-CH2-S-S-CH2-CH-CO.O-R
CA) NH.R~ NH.R~
where R represents an amino-reactive leaving group selected from lower alkyl phosphate and electronegatively substituted phenyl, and R' represents a bulky, N-protectant group such as carbobenzoxy, benzenesulfonyl, toluenesulfonyl, t-butyloxycarbonyl, fluorene-methoxycarbonyl, etc., as commonly used in protein chemistry. The reagents have a sufficiently short chemical chain length between respective amino-reactive leaving groups that they do not effect cross-linking between different hemoglobin tetramers to form 128 kd products (intermolecular cross-linking), only reaction with different (3-sub-units of the same tetramer.
The invention also provides a process of modifying hemoglobin which comprises reacting hemoglobin, in its deoxy state, with a modifying reagent of formula A give above. The acylation reaction occurs at amino acid residues in the diphosphoglycerate (DPG) binding site of the hemoglobin, specifically at the E-amino groups of lys-82 in the S
~3-subunits, and produces some cross-linked product of the general formula B:
Lys-(38~-NH.co . CH- CAL- S
r d, a NMR' Lys_(~'82-NW-Cv.CN ~CN1'S
I
NHft along with modified products having disulfide linkages in side groups, of general formula C:
(C) I '' NNR' t~NfZ~
In the general formulae, the symbol ~ ~,~ represents tetrameric hemoglobin. The group -Lys-~3-82-NH represents the lysine residues at position 82 on the respective ~i-globin chains of hemoglobin L~S._ ~8~.-IVN.Cp, iH. CNl_$-S-GNz. iN _ CDOH
NHR' NH2~
y, ~yS-(~ ~Z-NI-~.CO.CH.CN . S-S-Cl~ .CI-~- COON
with linkage to the side groups through the E-amino group thereof.
wo ~rr~o6s rcric~9aromo Another aspect of the invention is the modified hemoglobins so produced, which are novel products, represented by formulae B, and C
given above.
A further aspect is the process of preparing modified hemoglobin having side chains with terminal sulfhydryl groups bonded to ~i-iys-82 and/or Vii'-lys-82, which comprises subjecting modified hemoglobins of formulae B and/or C, to reduction so as to effect reductive cleavage of the disulfide bond. The modified hemoglobin so formed, of general formula D:
NN. ~o . ~ N - t NL- S H
d, ~ a NHR, rvN. co.cN-c~ly-$H (D) rt H R
is then reactable with any of a wide variety of biochemically active compounds, to form a conjugate administrable to a patient as a means for delivering the biochemically active compound to the patient.
Yet another aspect of the present invention is a process for preparing cross-linked tetrameric hemoglobin having cross-links between respective lysine-82 groups of the ~i-globin chains thereof, which comprises oxidizing the product of formula D given above, to re-form the disulfide bond. The cross-linked product so formed, which is the product of formula B given above, also constitutes an aspect of the present invention. This product B is a hemoglobin tetramer stabilized with disulfide cross-links to inhibit dissociation into dimeric sub-units. The disulfide cross-link resembles the natural disulfide cross-link present in many other naturally occurring proteins, and effecting a degree of conformational stability thereon.
The reagents of the present invention do not react with the N-terminal amino groups (Val-1) as do reagents that are bis methyl phosphates derived from simple dicarboxylic acids. It is likely that the bulk of the N-protected amino group in the reagents produces additional selectivity based on steric effects.
X-ray crystallographic structures of deoxy hemoglobin reveal that the (3-Lys-82 E-amino groups are outside the protein at the interface between the DPG-binding site and the surrounding solution . By contrast, the oc-amino group of the N-terminal (3-Val-1 is further within the DPG-binding site. Modeling of the reagent into the structure of deoxy hemoglobin suggests that the reagents bind to the DPG site at the solution interface, limiting reaction to the lysine residues. The steric bulk of two Cbz amino-protecting groups in the reagents provides selectivity beyond that found with acyl phosphate monoesters toward amino groups in hemoglobin.
BRIEF DESCRIPTION OF THE DRAWINGS
Figure 1 is an anionic exchange HPLC chromatogram of the reaction mixture resulting from Example 2 below, run under conditions which do not dissociate uncross-linked hemoglobin tetramers;
Figure 2 is an HPLC chromatogram of the separated globin chains from the reaction mixture in Example 2 below;
Figure 3 is a chromatogram of separated globin chains from Example 3 below, taken at an early stage of the reaction; and Figure 4 is an HPLC chromatogram of the products of Example 4 below, taken at an early stage of the reaction.
DESCRIPTION OF THE PREFERRED EMBODIIVVIENTS
The preferred cross-linking reagent according to the present invention is N,N'-bis-carbobenzoxy-cysteinyl-bis-(methylphosphate), sodium salt of formula I:
O O O O
I l ll ~I
Na+ 'O-l~~ O-C-CH-CH2-S-S-CH2-CH-C-O-P-O- +Na OCH3 NH I~ H OCH3 (I) C=O C=O
I I
O. CH2. C6H5 O. CH2. C6H5 This new reagent is referred to hereinafter as "ZCMP" . It be prepared from the reaction of the bis-acid chloride of N-protected cystine with dimethylphosphate followed by O-demethylation with methyl iodide in acetone. ZCMP is an example of a compound of general formula A
above in which R represents methylphosphate and R' represents carbobenzoxy.
Other preferred reagents according to the invention are those in which R is an electronegatively substituted phenyl group of general formula pZo where Z represents one or more independently selected electronegative groups having positive Hamnnet sigma values, and n is an integer from 1-5.
Examples of suitable groups Z are acetanudo (at the ortho or meta positions), acetoxy, acetyl, carbomethoxy, carboxy, halo, cyano, ethoxy (at the ortho or meta positions), hydroxy (at the ortho or meta positions), vitro, phenyl, trifluoromethyl and trimethylammonio. Preferred as substituent group Z are carboxyl, phosphonate, sulfonate, sulfate, phosphonate and halogen. Two or three such substituents are preferred, and especially cases where one of the substituents is carboxyl. When only one such substituent is present, it is preferred that it is located in the position orkho to the ester linkage to the aromatic nucleus. Most preferred for group R according to this embodiment is dibromosalicylate.
The hemoglobin which is used in the process of the present invention is preferably human hemoglobin, although the invention is applicable to other types of hemoglobin also, such as bovine hemoglobin and porcine hemoglobin and other animal hemoglobins. The source of the WO ~~~ PCT/CA98/01020 hemoglobin is normally red blood cells, although hemoglobin obtained by genetic engineering, recombinant techniques is also useful.
The cross-linked hemoglobin so formed, with the disulfide bonds intact, can be safely administered to human patients as a hemoglobin-based oxygen Garner.
Alternatively and preferably, however, the cross-linked hemoglobin is subjected to reductive cleavage so as to cleave the disulfide bonds, and form terminal sulfliydryl groups on the side chains bonded to a specific site of a specific globin chain. The cleaved product is then reacted with a biochemical molecule, utilizing the terminal sulfhydryl group, and administered to the body to act as a delivery medium for delivery of the biochemically active compound to the body.
The attachment of the biochemically active compound to the modified hemoglobin according to the present invention utilizes sulfhydryl bonds, located at the terminus of side chains remote from the point of attachment to the globin chains of the hemoglobin, and hence available for ready reaction with biochemically active compounds. The preferred linkage is a disulfide link, formed from the sulfhydryl group of the hemoglobin side chain and a sulfhydryl group of the biochemically active compound, or a sulfhydryl group of a linker or spacer molecule to which the biochemically active compound is in turn linked. A disulfide bond is slowly reduced by reducing agents present in human serum, so that a biochemically active compound so linked to the hemoglobin is slowly released into the blood stream. Reagents and conditions for formation of wo ~n3o6s rcric~9s~omo m disulfide bonds are well known in the art. Release of the biochemically active molecule from the hemoglobin, in order for it to exhibit its biochemical activity, is not necessary, in many cases. The conjugate with hemoglobin may exhibit the biochemical activity of the conjugant.
Biochemically active molecules which include sulfhydryl groups in their native structure include a wide variety of proteinaceous compounds which incorporate cysteine residues. These include atrial natriurectic factor (ANF), antithrombotic peptides such as RGDW; antiproliferatives or antimetastics such as RGD polymers or analogues thereof, and GRDGDS
or analogues thereof; antihypertensives-renin inhibitors such as Boc-HPFHL-CH(OH)-CH2-VIH or analogues thereof; human growth hormone releasing factor analogues; anorexigenics; vasoconstrictors such as arginine vasopressin; vasodilators such as angiotensin converting enzyme inhibitors; and anti-AIDS drugs such as HIV protease inhibitors.
Other sulthydryl group containing therapeutically active compounds which can be conjugated to the modified hemoglobin of the invention include captopril ( 1-(3-mercapto-2-methyl-1-oxopropyl)-L-proline).
The reactions of ZCNiP with hemoglobin follow the patterns of other anionic electrophiles. The reagent reacts efficiently only with the deoxy form. Its acylating reaction occurs at residues in the DPG binding site at the E-ariiino groups of Lys-82 in the (3 subunits.
The reaction of ZCMP with carbonmonoxy hemoglobin gives only a very small amount of product under the conditions that extensively modify the deoxy form. The product that does form is not cross-linked.
This result is consistent with the conformational change of hemoglobin in going from the R state to the T state. When deoxy hemoglobin binds to ligands such as oxygen and carbon monoxide, the extensive quaternary structural change leads to contraction of the DPG binding site. As a consequence, the DPG binding site is not large enough to be accessed by such a bulky reagent.
The disulfides of the two [3-chain-modified hemoglobins, compounds B and C above, show different reactivity with mild reducing agents such as (3-mercaptoethanol. With this reagent, the linear disulfide compound C is reduced to form compounds with terminal sulfhydryl groups (compound D) whereas the cross-linked disulfide B remains largely unaffected. The reaction mechanism and accessibility of the S-S bonds of modified hemoglobins explains this difference. Reduction of a disulfide by thiol reagents proceeds in two steps. A mixed disulfide of the cleaved disulfide and mercaptoethanol is an intermediate. In the thiol-disulfide exchange process, a large excess of the reagent is required to drive the reaction to completion.
For the cysteinyl hemoglobin with no cross-links, one end of the reagent is attached to J3Lys-82. The unreacted portion of the large, hydrophilic reagent is probably out of the DPG binding site. Therefore, the disulfide is~ accessible to 2-mercaptoethanol. On the other hand, if the (3 subunits of hemoglobin are cross-linked as the bis cysteinyl derivative, the S-S bond within the DPG cleft becomes less accessible to the thiol reagent. The DPG binding site protects the disulfide from reduction, and the reaction of that disulfide bond with 2-mercaptoethanol is blocked.
The S-S bond of the cross-linked hemoglobin is cleaved with more effective reducing reagents such as dithiothreitol (DTT). When dithiothreitol is used to reduce the S-S bond, the first step is also a thiol-disulfide exchange as with 2-mercaptoethanol. However, once the intermediate is formed, a second molecule of reagent does not participate in the reaction. Instead, an intramolecular reaction can occur, leading to the formation of the stable cyclic disulfide of DTT. The intramolecular process has a large entropic advantage in its favor. Since the cross-linked hemoglobin was reduced without the addition of denaturing reagents, the S-S bond is near the outside of the DPG cleft of the cross-linked hemoglobin and is exposed to solvent.
In any event, the end product of reduction of both compound B and compound C is a modified hemoglobin with terminal sulfhydryl (thiol) groups, of general formula D above.
Depending upon the choice of protectant group R' in the modifying reagent, it may be desirable to remove it prior to administering products of the present invention to a patient. This will depend largely on toxicity considerations. Removal of the protectant groups can be accomplished by standard methods employed in peptide chemistry.
The oxidation of thiols to disulfides by oxygen normally proceeds only in the presence of catalytic quantities of metal ions such as iron and copper. The rate of the oxidation of thiols in the same molecule depends on the distance between the thiol groups. In the present case, it has been found that the modified hemoglobin with two free sulfhydryl groups attached at (3-Lys-82 is oxidized spontaneously by atmospheric oxygen, quantitatively producing the cross-linked tetramer. It is possible that the iron of the heme facilitates the reaction, especially that which is present as Fe(III) met-hemoglobin. The sulfliydryl groups produced by reduction iii the process of the present invention remain in close spatial proximity in order to form the disulfide bond between subunits by oxidation. Cleavage of the disulfide at each'site, followed by oxidation permits spontaneous formation of the cross-link between dimers. This produces a much higher yield of cross-linked materials and provides an added benefit of the use of such reagents. Accordingly, a preferred process for making an HBOC according to the present invention comprises reacting human deoxy hemoglobin with a disulfide group containing protein modifying reagent as previously described, to form a mixture of cross-linked and non-cross-linked modified hemoglobin (products B and C) above, subjecting the mixture to reductive cleavage of the disulfide bonds to form a modified hemoglobin of general formula D, and then oxidizing this modified hemoglobin to form disulfide cross-linked hemoglobin. Such a process is capable of producing substantially quantitative yields of cross-linked hemoglobin.
The introduction of specific chemical alterations at defined sites within a protein is complementary to methods based on genetic engineering. The design of the modifying reagent ZCNiP of the preferred embodiment of the invention permits site selection based on charge and steric factors. The fact that ZCMP is an amino acid derivative permits chemical techniques to be used that are extended from the chemistry of peptide formation. A wide variety of side chains, as well as longer peptides for conjugation, can be implemented in combination with the convenient methods developed for producing the mixed phosphate-amino acid anhydride.
The use of the disulfide-based reagent in the present study adds fiuther possibilities for applications of cross-linking by converting sites that contain lysyl side chains into those connected as disulfides and also, by reduction, to sites for bioconjugation.
The invention is further described, for illustrative purposes, in the following specific examples.
EXPERIMENTAL PROCEDURES
General Methods. Water was doubly distilled and deionized. All pH
measurements were standardized against calibrated buffers using a combination glass electrode. Molecular mechanics was employed to obtain preferred conformations based on several initially estimated structures of bis(N-Cbz)-cysteinyl bis(methyl phosphate). The coordinates of deoxy hemoglobin of Fermi and Perutz (Re f. 1, infra) from the Brookhaven protein database were used for visualization of the structure of the protein.
Melting points were obtained in a calibrated oil bath apparatus. Proton NMR spectra were recorded at 200 MHz and 300 MHz with chemical shifts reported relative to TMS or DSS. '3C NMR spectra were recorded WO 99/23065 PCT/CA98/IIlOZO
on the same instruments at 50 MHz and 75 MHz. Carbon chemical shims were measured relative to the chloroform-d with TMS at 0. 31P NMR
spectra were recorded at 120 MHz and chemical shifts are relative to 85%
phosphoric acid in water. Infrared spectra were recorded on a FT-IR
spectrometer in KBr pellets. Mass spectra were recorded by electron-impact (EI) or fast atom bombardment ionization (FAB). The Mass Spectroscopy Laboratory, Department of Medical Genetics, University of Toronto provided electrospray ionization mass spectra. Chemical modification of hemoglobin and analysis followed general procedures as reported for related materials. (Refs. 2 and 3, infi-a) Examule 1- Synthesis of N.N'-bis-Cbz-cystein l~bis ,(,Sodium MethXt Phosphate) (ZCMP,~
N,N'-bis-Cbz-cysteinyl dichloride (1.0 g, 1.8 mmol) and sodium dimethyl phosphate (0.54g, 3.6 mmol; from trimethyl phosphate and one equivalent of sodium iodide in dry acetone) were suspended in 30 mL dry tetrahydrofuran at 0° C under nitrogen and stirred for 1 hr. The resulting precipitate of sodium chloride was removed by filtration.
The filtrate contained the reaction product N-Cbz-cysteinyl bis-dimethyl phosphate, 2 Sodium iodide (2.2 g, 14.6 mmol) was added to the filtrate to replace one methyl group at each phosphate with sodium.
The mixture was stirred at S° C for 48 hr. Solvent was removed by rotary evaporation. The resulting solid was crystallized from acetone-ether, producing an off white powder. This was collected and washed three times with acetonitrile. The powder was dried in vacuum to give 1.0 g (1.35 mmol, 74% yield) N-Cbz-cysteinyl bis (sodium methyl phosphate) (ZCMP) as a white solid, mp > 200 °C. IR (KBr) C~ 1675 cni 1, 1695 crri'; 1H NMR (200 MHz, D20, 87.26 {s, lOH, 2C6H5), 4.88 (s, 4H, 20CH2Ph), 4.44 (m, 4H, NH and NCH), 3.45 (dd, 6H, JP-H = 11.5 Hz, 20CH3), 2.70-3.25 (m, 4H, SCH2); 13C NMR (121 MHz, D20) 8168.3 (d, JP-C = 9.7 Hz, P-O-C=O), 157.29 (C=O), 135.9, 128.4, 128.3, 127.7, 67.1, 53.9 (d, JP-C = 6.4 Hz, OCH3), 37.8; 31P NMR (121 MHz, D20) 8-5.4 (q, JP-H = 11.3 Hz); FAB mass (-, glycerol) 717 (38.0, M-Na+).
Example 2 - Preparation of deoxy hemoglobin and its reaction with ZCMP
A solution of hemoglobin (80 mg/mL in 6 mL O.1M pH 8 MOPS) in a SO-mL rb flask was immersed in an ice-water mixture. This was connected to a rotating reactor containing tubes for inflow and outflow of gasses. Humidified oxygen was then passed through the solution for one hr with the flask illuminated by a tungsten lamp. The resulting oxy hemoglobin was converted to the deoxy form by passing a stream of humidified nitrogen over the rotating solution for 3 hr at 37°C.
A solution of ZCMP was added over 15 min to a solution of hemoglobin in buffer {0.5 mM) so that the final conc. of ZCMP in the mixture was 0.7 mM and that of hemoglobin was 0.25 mM (0.1 M MOPS, pH 8.0). Other buffering agents of the kind known as Good buffers may be used in lieu of MOPS, e.g. sodium borate, but more chemically reactive conventional buffers such as Tris and bisTris will react adversely with ZCMP or other protein-modifying agents according to the invention.
The buffered hemoglobin solution was kept at 37 °C. For reactions with deoxy hemoglobin, the reagent was degassed and was introduced under nitrogen. The reaction was carried out under flowing nitrogen. For reactions with carbonmonoxy hemoglobin, the reaction solution was saturated initially with carbon monoxide. After the ZCMP
was added to the solution of hemoglobin, the reaction was continued for 2 hr. The flask was then disconnected from the rotating reactor and carbon monoxide was introduced. The solution was passed through a column of Sephadex G-25 equilibrated with 0.1 M pH 8 MOPS to remove excess reagent. The resulting material (ca. 20 mL) was collected in a vial.
Analysis of the resulting modified hemoglobin was done with a combination of reversed-phase HPLC and ion exchange HPLC following previously reported procedures. (2) Product Analysis Extent of cross-linking. A sample of the reaction product (1.0 mL) was passed through a gel filtration column of Sephadex-100 (superfine) that had been equilibrated with 1.0 M magnesium chloride.
Under these conditions hemoglobin that is not cross-linked dissociates into a[3 dimers. The dimers elute more slowly than do cross-linked tetrameric species. The extent of cross-linking of globin chains was also determined by polyacrylarnide gel electrophoresis in the presence of sodium dodecyl sulfate (SDS PAGE ) on Mini-Protean II Ready Gels (12%
polyacrylamide, 0.375 M Tris-HCI, pH 8.8) as reported previously. (Ref.
4, infra) The hemoglobins and globins from HPLC preparations were WO 99!13065 PCT/CA98/01020 denatured in 0.065 M Tris-HC1, pH 6.8, 2% SDS, 10-v/v glycerol.
Approximately 20 p,g of protein was applied to each lane of the gel and processed at 200 V for 1 hr. Protein bands on the gel were stained with Coomassie brilliant blue R-250.
Analytical and preparative separation of globin chains.
Modified hemoglobins were separated as intact tetramers by anion exchange HPLC on a SynChropak AX300 column (250 x 4.6 mm) using a mixture of 0.025 M bis-tris and 0.025 M tris with gradients starting from pH 8.5 to pH 6.7. The effluent was monitored at 540 nm. Heme and globin chains were separated by reversed phase HPLC using 330 A pore C4 Vydac columns (250 x 4.6 mm for analytical and 250 x 12 mm for preparative). Developers contained 0.1 % trifluoroacetic acid and various gradients of acetonitrile starting at 20% and ending at 60%. The effluent was monitored at 220 nm. Globin chains were recovered from the effluent by lyophilization.
Digestion of globin chains. Globin chains were dissolved in 8 M urea to increase susceptibility to hydrolysis and kept at room temperature for 2-4 hr. The solution was then diluted to 2 M urea with 80 mM ammonium bicarbonate buffer at pH 8.5. Trypsin (2% of total protein) was added, and the solution was digested for 24 hr at room temperature.
The hydrolysate was heated in boiling water for 2 min, diluted to 1 M urea with 80 mM ammonium bicarbonate buffer, and further digested with endoproteinase Glu-C (1% of total protein) for another 72 hr at room temperature. The hydrolysates were filtered before injection into the HPLC.
Chromatography of peptides. Peptide fragments were separated by analytical HPLC using reversed phase C 18 columns (3 .9 x 300 nun). Developers consisted of 0.1% trifluoroacetic acid in water with gradients of acetonitrile from 0 to 100% over ca 2 hr. The HPLC effluent was monitored at 214 and 280 nm.
Combination of ZCMP with deoxy hemoglobin (3:1 reagent:
protein) in aqueous buffer as described above produced a set of modified hemoglobins. Under the same conditions, carbonmonoxy hemoglobin underwent very little reaction. The resulting proteins from reaction of deoxy hemoglobin and ZCMP were separated by anion-ion exchange HPLC (AX-300). Enzymic digestion and mass spectral analysis were used to determine the sites of the modifications resulting from reaction with ZCMP. The HPLC chromatogram of the reaction mixture containing intact tetramers is presented as Figure I of the accompanying drawings and shows that the solution contained only a small amount of unreacted hemoglobin (aa(3(3) along with two major peaks corresponding to modified tetramers.
Two minor products elute after the major constituents.
Further analysis of the components of the modified proteins by reversed-phase HPLC indicates that the two major products have native a chains along with modified (3 chains (determined by comparison with unmodified protein).
Figure 2 shows the results of HPLC analysis of the reaction mixture under conditions that separate the globin chains. Structural analysis of each component (from digestion, SDS-PAGE, and peptide analysis) indicates that there are two (3-modified tetrameric products.
Peaks 1 and 2 correspond to modified (3 subunits. The first peak is material that is modified by reaction with ZCMP without cross-linking (the cysteinyl amide, compound corresponding to general formula C above).
The second contains the two subunits cross-linked as the cysteinyl bis amide (Compound B above). Enzylnic digestion followed by peptide analysis reveals that in both peaks, modification is at the E-amino group of lysine-82 of the ~i subunits. Two minor products, peaks 3 and 4, were shown by a similar analysis to be modified a subunits. Ion-spray mass spectral analysis (Ref. 5, infra) of material from reversed-phase HPLC
gives the molecular weight of the cross-linked (3 chains as 32208, consistent with two (3 chains linked as the N,N'-CBZ-cysteinyl bis-amide.
The peaks from the material that is not cross-linked are consistent with a species in which an amide has formed from reaction of ZCMP with the lysyl-82 E-amino group while the second acyl group of the reagent has undergone hydrolysis (Table 1).
WO 99/23065 PCT/CA98/OlOZO
TABLE 1 - Ion-sprays spectral parent peaks of modified g~obin chains obtained from reaction of deoxy hemoglobin with ZCMP
GLOBIN CHAIN OF FOUND EXPECTED
HEMOGLOBIN (Molecular weight) (Molecular weight) Unmodified (3- 15868.80 ~ 1.50 15867 subunits Modified ~i-subunits16359.01 t 1.50 16357 Cross-linked ~3- 32207.78 ~ 1.87 32206 subunits Unmodified a- 15127.24 t 1.55 15126 subunits Modified a-subunits15616.19 ~ 1.55 15616 Where a cross-linked hemoglobin of the kind of Compound B
according to the invention is not to be subjected to reductive cleavage of its disulfide crosslinks but, rather, is to be used as tetrameric (e.g., as an HOBC), the material may be reacted fiuther with an a cross-linker such as 3,5 DBSF. Since ZCMP reacts with hemoglobin primarily at the ~3 chains and 3,5 DPSF leads to cross-linking at the a Lys 99 positions, the result is a doubly cross-linked (or doubly-modified) hemoglobin. As reported previously by Kluger, et al. (Ref. 3, infra), if the DPG site is blocked (as it would be, given a Cbz-cysteinyl cross-link between the (3Lys 82 residues) then 3,5 DBSF cross-links only at the aLys 99 residues. Unintended cleavage of the Cbz-cysteinyl link in such a doubly cross-linked hemoglobin would still leave a fumaryl link between the a chains to keep the tetramer together.
Example 3 - Reduction of the disulfide of bis-c stein3rl deox~r hemoglobin with 2-mercaotoethanol.
2-Mercaptoethanol (0.018 g) was dissolved in 1 mL 0.1 M
pH 8.0 MOPS. 0.1 mL of the solution was added to one mL of a solution of the modified hemoglobins from the reaction of deoxy hemoglobin with ZCMP. The reaction mixture was stirred at 5 °C. Samples were analyzed by reversed-phase HPLC.
Progress of the cleavage reaction was followed by reversed-phase HPLC. When the modified hemoglobins from the reaction of ZCMP
with deoxy hemoglobin were treated with a 20 fold excess of 2-mercaptoethanol for 1 hr, the modified but not cross-linked hemoglobin was reduced to yield t-wo products in approximately 1:1 ratio (Figure 3 shows a chromatogram from analysis early in the course of the reaction).
As peak 1 disappeared, two new peaks {peak 5 and 6) appeared with shorter retention times. The structures of these products were established by electrospray ionization mass spectral analysis. Peak 5 is the reduced (3 chain corresponding to the desired product that results from the cleavage of the disulfide bonds. The reaction of 2-mercaptoethanol with modified (but not cross=linked hemoglobin is summarized in Scheme 1. The formation of a mixed disulfide intermediate and cleavage.occurs only with material that is not cross-linked by 1. Peak 6 is the mixed disulfide intermediate (of mercaptoethanol and modified and hemoglobin), with a parent mass of 16178 ~ 2 (calcd 16180). Such a mixed disulfide is consistent with formation of intermediates by this reagent. (21,22). Thus, the possible products are reduced of cross-linked hemoglobin and two hemoglobins with mixed disulfides. However, the reaction of the disulfide of cross-linked hemoglobin with 2-mercaptoethanol proceeded very slowly under the same conditions. Peak 2, corresponding to cross-linked hemoglobin, did not decrease. The calculated mass of the modified ~3 chain with a cleaved sidulfide, a cysteinyl amide of the ~i subunit of hemoglobin, is 16,105; found: 16106.71.4.
The modified protein mixture from the reaction of ZCMP
with deoxy hemoglobin followed by treatment with an excess of 2-mercaptoethanol for a few minutes was analyzed as follows. Mass spectra reveal that Peak 5 is the (3 chain corresponding to the product that results from the cleavage of the disulfide bonds derived from the protein modified by ZCMP.
s-s sH SH
« p « HSCH2CHZOH « p « HSCH2CH20H
P «
s-s P
SSCHiCHzOH SH
« ~ « ~ HSCHZCH20H
- SLOW
a Examule 4 - Reduction of modified hemoglobin with dithiothreitol and subsequent re-oxidation Dithiothreitol (DTT) (0.073 g, four equivalents) was dissolved in 1 mL 0.1 M pH 8.0 MOPS. 0.01 mL of the DTT solution was added to 1 mL of the solution of modified hemoglobins from the reaction of deoxy hemoglobin with ZCMP. The reaction mixture was stirred at 5 °C and the sample analyzed by reversed-phase HPLC. After 15 min, the product was passed through a column of Sephadex G-25 equilibrated with 0.1 M pH 8.0 MOPS to remove excess dithiothreitol. The sample was collected and analyzed again by reversed-phase HPLC.
Dithiothreitol (DTT) is a more effective reducing agent than 2-mercaptoethanol. In this experiment with DTT, all disulfide bonds were cleaved within 15 minutes. The reversed phase HPLC showed none of the original peaks derived from the (3-subunits. There was a single product peak at the position of the cysteinyl derivative of the ~i subunit. This is the same species generated in the reaction with 2-mercaptoethanol and with the same mass (16,105). The bis cysteinyl amide (aa~i-Lys-82-cys-S-S-cys-(Lys-82)-(3) is cleaved at the disulfide.
Figure 4 shows the reversed-phase HPLC chromatogram of the products from an early stage in the reaction with DTT (showing some remaining unreacted [3 subunits are present). The peaks are numbered as in Figure 3. The bis sulfide now appears as peak 5 but, as required, the intermediate from 2-mercaptoethnaol (peak 6) is not present. The reaction pattern with DTT is summarized in Scheme 2.
S--S SH
DTT
a a a a s-s p sH
SH
a ~ a S DTT
I ~ a a S
SH
Gel filtration chromatography was used to separate modified protein from excess DTT after reduction. The product in the presence of air and the absence of DTT is rapidly oxidized to produce once again aa(3-Lys-82(E-NH-cys-S-S-cys-( E-NH-Lys-82)(3 quantitatively. HPLC
reverse phase analysis after 15 minutes reveals the decrease of peak 5 (modified, not cross-linked) and a large increase in peak 2, that of the cross-linked species. Re-treatment of the protein solution with DTT once again gives the disulfide-cleaved products exclusively (HPLC analysis).
Therefore, the reduction-oxidation procedure is an efficient way to convert material that is not cross-linked into cross-linked material (Scheme 3).
Scheme 3 SH
a~~
a a ~a SH
SH
a wo ~n3o6s ~cTicw9sroiozo References (1) Fermi, G. and Perutz M.F. {1984) The crystal structure of human deoxyhaemoglobin at 1.74 Angstroms resolution. J. Mol.
Biol., 175, 159-174.
(2) Jones, R.T. (1994) Structural characterization of modified hemoglobins. Methods in Enzymology, 231, 322-343.
(3) Jones, R.T., Shih D.T., Fujita T.S., Song Y., Xiao H., Head C.
and Kluger R. (1996) A doubly cross-linked human hemoglobin.
Effects of crosslinks between different subunits. J. Biol. Chem., 271, 675-680.
(4) Kluger, R. and Song Y. (1994) Changing a protein into a generalized acylating reagent. J. Org. Chem., 59, 733-736.
(5) Fenn, J.B., Mann M., Meng C.K., Wong S.F. and Whitehouse C.M. (1989) Electrospray ionization for mass spectrometry of large molecules. Science, 246, 64-71.
Claims (10)
1. A reagent for modifying hemoglobin to produce complexes including disulfide linkages, corresponding to the general formula (A):
where R represents an amino-reactive leaving group selected from lower alkyl phosphate and electronegatively substituted phenyl, and R1 represents a bulky, N-protectant group.
where R represents an amino-reactive leaving group selected from lower alkyl phosphate and electronegatively substituted phenyl, and R1 represents a bulky, N-protectant group.
2. A reagent for modifying hemoglobin according to claim 1, wherein said N-protectant group is selected from the group consisting of carbobenzoxy, benzenesulfonyl, toluenesulfony, t-butyloxycarbonyl and fluorene-methoxycarbonyl.
3. A reagent for modifying hemoglobin according to claim 1, wherein R is an electronegatively substituted phenyl group of general formula where Z represents one or more independently selected electronegative groups having positive Hammet sigma values, and n is an integer from 1-5.
4. A reagent according to claim 3, wherein Z is selected from the group consisting of o-acetamido, m-acetamido, acetoxy, acetyl, carbomethoxy, carboxy, halo, cyano, o-ethoxy, m-ethoxy, o-hydroxy, m-hydroxy, nitro, phenyl, trifluoromethyl and trimethylammonio.
5. A reagent according to claim 1, wherein R represents methylphosphate and R1 represents carbobenzoxy, corresponding to the formula (I):
6. A process for preparing a disulfide cross-linked hemoglobin of the general formula (B):
and a modified hemoglobin having side group disulfide linkages, of general formula (C):
by reacting deoxy hemoglobin with a reagent according to claim 1.
and a modified hemoglobin having side group disulfide linkages, of general formula (C):
by reacting deoxy hemoglobin with a reagent according to claim 1.
7. A disulfide cross-linked hemoglobin of the general formula (B):
wherein R1 represents a bulky N-protectant group.
wherein R1 represents a bulky N-protectant group.
8 A modified hemoglobin having disulfide linkages in side groups, of general formula (C):
wherein R1 represents a bulky N-protectant group.
wherein R1 represents a bulky N-protectant group.
9. A process for preparing modified hemoglobin having side chains with terminal sulfhydryl groups bonded to .beta.-lys-82 and/or .beta.'-lys-82 by reacting a disulfide cross-linked hemoglobin according to claim 7 with a reducing agent so as to effect reductive cleavage of the disulfide bond forming terminal sulfhydryl groups which are available for reaction with selected biochemical molecules.
10. A process for preparing modified hemoglobin having side chains with terminal sulfhydryl groups bonded to .beta.-lys-82 and/or .beta.'-lys-82 by reacting a modified hemoglobin according to claim 8, with a reducing agent, so as to effect reductive cleavage of the disulfide bond forming terminal sulfhydryl groups which are available for reaction with selected biochemical molecules.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US6412297P | 1997-11-03 | 1997-11-03 | |
US60/064,122 | 1997-11-03 | ||
PCT/CA1998/001020 WO1999023065A1 (en) | 1997-11-03 | 1998-11-03 | Hemoglobin with chemically introduced disulfide cross-links and preparation thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2308277A1 true CA2308277A1 (en) | 1999-05-14 |
Family
ID=22053712
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002308277A Abandoned CA2308277A1 (en) | 1997-11-03 | 1998-11-03 | Hemoglobin with chemically introduced disulfide cross-links and preparation thereof |
Country Status (4)
Country | Link |
---|---|
AU (1) | AU1015699A (en) |
CA (1) | CA2308277A1 (en) |
GB (1) | GB2346144A (en) |
WO (1) | WO1999023065A1 (en) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0125793D0 (en) * | 2001-10-26 | 2001-12-19 | Panzeri Ezio | Method |
US7235639B2 (en) | 2003-04-23 | 2007-06-26 | Ezio Panzeri | Hemoglobin conjugates |
KR20240015482A (en) * | 2022-07-27 | 2024-02-05 | 삼성에스디아이 주식회사 | Positive electrode, and rechargeable lithium battery including the same |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5399671A (en) * | 1992-11-18 | 1995-03-21 | Kluger; Ronald | Specifically crosslinked hemoglobin with free functionality |
-
1998
- 1998-11-03 CA CA002308277A patent/CA2308277A1/en not_active Abandoned
- 1998-11-03 AU AU10156/99A patent/AU1015699A/en not_active Abandoned
- 1998-11-03 GB GB0010464A patent/GB2346144A/en not_active Withdrawn
- 1998-11-03 WO PCT/CA1998/001020 patent/WO1999023065A1/en active Application Filing
Also Published As
Publication number | Publication date |
---|---|
GB2346144A (en) | 2000-08-02 |
GB0010464D0 (en) | 2000-06-14 |
WO1999023065A1 (en) | 1999-05-14 |
AU1015699A (en) | 1999-05-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU665760B2 (en) | Specifically beta-beta cross-linked hemoglobins and method of preparation | |
US6017943A (en) | Hemoglobin crosslinkers | |
AU635204B2 (en) | Novel compounds and methods of preparing a metal-radionuclide-labelled protein | |
US4786684A (en) | Benzylthioether-linked solid support-bound thiol compounds and method for peptide synthesis | |
Hojo et al. | Development of a Linker with an Enhanced Stability for the Preparation of Peptide Thioesters and Its Application to the Synthesis of a Stable-Isotope-Labelled HU-Type DNA-Binding Protein. | |
US5399671A (en) | Specifically crosslinked hemoglobin with free functionality | |
US5352771A (en) | Hydrolysis of peptide bonds using Pt (II) and Pd (II) complexes | |
CA2195005C (en) | Multifunctional cross-linking reagents for hemoglobin, and cross-linked hemoglobin conjugates | |
CA2308277A1 (en) | Hemoglobin with chemically introduced disulfide cross-links and preparation thereof | |
KR20030046389A (en) | Nucleophile-stable thioester generating compounds, methods of production and use | |
DE102006035083A1 (en) | Protein binding methotrexate derivatives and medicaments containing them | |
JPH0632790A (en) | Biotin-introducing reagent and method for purifying synthetic peptide with the same | |
US5917020A (en) | Bis-tetrameric hemoglobin and reagents for its production | |
Atherton et al. | Peptide synthesis. Part 6. Protection of the sulphydryl group of cysteine in solid-phase synthesis using N α-fluorenylmethoxycarbonylamino acids. Linear oxytocin derivatives | |
WO2007065265A1 (en) | Cross-linking reagents for hemoglobin and hemoglobin products cross-linked therewith | |
KR930008096B1 (en) | S-sulfonated calcitonin derivatives | |
Kluger et al. | Efficient chemical introduction of a disulfide cross-link and conjugation site into human hemoglobin at β-lysine-82 utilizing a bifunctional aminoacyl phosphate | |
Suzuki et al. | Spectral properties of carbon monoxide or cyanide complexes of cytochromes c′ from denitrifying bacteria | |
EP0443598B1 (en) | Peptides inhibiting the blood coagulation, their process of preparation and their use | |
SANO | THE CYTOCHROME c MOLECULEf | |
AU7013900A (en) | Method for coupling, in solution, a peptide with at least another compound and uses thereof | |
Sano | Cytochrome C and porphyrin-peptides: characterization of cytochrome C and status of studies on its chemical synthesis | |
Boon | Semisynthesis of cytochrome c analogues | |
Westerhuis | Biologically active complexes from specifically modified cytochrome C fragments | |
Teytelboym | Tetrafunctional cross-linking reagents, reaction with hemoglobin and the formation of hemoglobin bis-tetramers |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
FZDE | Discontinued |